PROM1 and lung cancer: Ahmad A et al.10 demonstrated that erlotinib-resistant lung cancer cells possessed enhanced metastatic potential and displayed elevated expression levels of stemness-associated genes, including Nanog, CD133, Oct4, and Sox2. Moreover, our previous study confirmed that gefitinib-resistant lung cancer cells exhibited enhanced self-renewal capacity and resistance to chemotherapy 11.